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ESR1 mutations in metastatic lobular breast cancer patients
Christine Desmedt1,2, Julien Pingitore2, Françoise Rothé1, Caterina Marchio3,4, Florian Clatot5,6, Ghizlane Rouas1, François Richard 1,
François Bertucci7, Odette Mariani3, Christine Galant8, Charlotte Fribbens9,10, Ben O’Leary9,10, Gert van den Eynden11,
Roberto Salgado1,11, Nicholas C. Turner9,10, Martine Piccart12, Anne Vincent-Salomon3, Giancarlo Pruneri13,14,15, Denis Larsimont16 and
Christos Sotiriou1
Invasive lobular breast cancer (ILC) represents the second most common histology of breast cancer after invasive ductal breast
cancer (IDC), accounts for up to 15% of all invasive cases and generally express the estrogen receptor (ER, coded by the ESR1 gene).
ESR1 mutations have been associated with resistance to endocrine therapy, however these have not been speciﬁcally evaluated in
ILC. We assessed the frequency of ESR1 mutations by droplet digital PCR in a retrospective multi-centric series of matched primary
tumor and recurrence samples (n= 279) from 80 metastatic ER-positive ILC patients. We further compared ESR1 mutations between
IDC and ILC patients in metastatic samples from MSKCC-IMPACT (n= 595 IDC and 116 ILC) and in ctDNA from the SoFEA and
PALOMA-3 trials (n= 416 IDC and 76 ILC). In the retrospective series, the metastases from seven patients (9%) harbored ESR1
mutations, which were absent from the interrogated primary samples. Five patients (6%) had a mutation in the primary tumor or
axillary metastasis, which could not be detected in the matched distant metastasis. In the MSKCC-IMPACT cohort, as well as in the
SoFEA and PALOMA-3 trials, there were no differences in prevalence and distribution of the mutations between IDC and ILC, with
D538G being the most frequent mutation in both histological subtypes. To conclude, no patient had an identical ESR1 mutation in
the early and metastatic disease in the retrospective ILC series. In the external series, there was no difference in terms of prevalence
and type of ESR1 mutations between ILC and IDC.
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INTRODUCTION
Invasive lobular breast carcinomas (ILC) account for up to 15% of
all invasive breast cancer (BC) cases and represents the second
most frequent histological subtype after invasive ductal BC (IDC),
the latter also being formally referred to as invasive breast
carcinoma of no special type.1 ILCs typically express the estrogen
receptor (ER, coded by the ESR1 gene) and lack HER2 ampliﬁcation.
These tumors further differ from IDC in terms of clinical
presentation, disease progression, and response to treatment.2
Recently, several studies on primary ILC have demonstrated that
these two subtypes also present differences in terms of genomic,
gene expression, protein, and immune features.3–8
Given the fact that ILCs are nearly exclusively ER-positive, those
patients are almost always treated with endocrine therapy. While
the majority of the patients do beneﬁt from these treatments, a
large proportion will present with de novo or acquired resistance.
Although several mechanisms of endocrine resistance have been
proposed,9,10 one of those that has been receiving more attention
during the last years thanks to the increasing sequencing
initiatives of metastatic breast tumors is represented by the
recurrent mutations in the ESR1 gene (reviewed by Jeselsohn
et al.11).
ER is a member of the nuclear receptor superfamily and acts as
a ligand-dependent transcription factor. Upon binding of estro-
gen, ER dimerizes and the α-helix of helix 12 is stabilized into an
active conformation, allowing the binding of co-activators. This
results in the binding of ER to several DNA sites to regulate the
transcription of a multitude of genes involved in several
physiological and cancer-related processes. The majority of the
ESR1 mutations are concentrated on two amino acids (Y537, D538)
in the ligand-binding domain. These mutations have been
reported to lead to ligand-independent activation.12
Mutations affecting the ESR1 gene have been detected mainly
in metastases from ER-positive/HER2-negative breast tumors, at a
frequency ranging from 5 to 25%, when considering series with
>20 interrogated metastases.5,13–18 The largest cohort of BC
metastases with information about the ESR1 mutational status is
the one derived from the prospective clinical sequencing initiative
from the Memorial Sloan Kettering Cancer Center (MSKCC-
IMPACT18), which reported mutations in 107/835 (12.5%)
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metastatic BC patients (source: cbioportal.org19,20). Besides the
detection in metastatic tissue, several studies have also inter-
rogated the presence of these mutations in circulating tumor DNA
(ctDNA) in institutional cohorts15,21,22 or in the context of clinical
trials.23–25 The prevalence of ESR1 mutations was much higher
here, ranging between 14.8 and 31.5% in the institutional series
and between 25.3 and 39.1% in the trials. Results are consistent
across the cohorts in reporting higher ESR1 mutation rates in
patients treated with aromatase inhibitors in the metastatic
setting.15,22
So far the prevalence of these mutations has been extremely
low in primary tumors, with 0.5% mutated samples detected by
next-generation sequencing (NGS) in the large cohort from The
Cancer Genome Atlas (TCGA, source: cbioportal.org3,19,20).
Recently, two studies using the more sensitive droplet digital
PCR (ddPCR) reported higher frequencies in primary tumors of 2.6
and 7%, respectively.21,26 Two series of primary cancers from
patients who recurred revealed also increased rates of 3 and 3.5%
using NGS.13,18 Of interest, the mutant allele frequencies were
generally very low in these primary tumors, rarely above 1%,
suggesting that these mutated cells likely represent a minor
subclone.
While the increased prevalence in the metastatic setting
suggests that these mutations are acquired, few studies have
extensively compared matched primary and metastatic samples to
exclude that the ESR1 mutations detected in the metastatic
disease were actually already present in a rare subclone of the
primary tumor.13,16,17 So far, the comparison on the highest
number of matched primary and metastatic ER-positive samples
was reported by Fumagalli et al.16 using a mutational hotspot
qPCR assay on 37 patients, and none of the 4 ESR1 mutations
present in the metastatic samples were detected in the matched
primary. However, given the higher rates of ESR1 mutations
detected with ddPCR, we hypothesized that deeper sequencing
methods could maybe identify additional matched mutations. If
the ESR1mutations were pre-existing in the primary tumor and led
to endocrine resistance, this would have important therapeutic
and monitoring implications.
Since tumors harboring ESR1 mutations may require a different
endocrine treatment strategy,27 it is of utmost importance to
identify these. However, no study has ever speciﬁcally evaluated
the presence and distribution of ESR1 mutations in metastatic ILC.
In this study, we therefore assembled a retrospective multi-centric
cohort of matched normal, primary and metastatic samples from
metastatic ER-positive ILC patients and evaluated the most
frequent ESR1 mutations using ddPCR. To further compare the
frequency and distribution of the mutations between IDC and ILC
patients, we interrogated the metastases from MSKCC-IMPACT18
and ctDNA from SoFEA and PALOMA-3.24
RESULTS
Characteristics of the retrospective metastatic ILC cohort
We retrospectively identiﬁed 129 metastatic ER-positive ILC
patients from 6 European institutions fulﬁlling the initial eligibility
criteria. From these patients, following block retrieval and central
pathology review, 94 were eligible. Sufﬁcient DNA was available
from the primary, the metastatic as well as normal tissue samples
for 80 patients. Whenever possible, we also collected samples
from involved axillary lymph nodes (Supplementary Figure 1). The
patients and samples (n= 279) characteristics are listed in Table 1
and Supplementary Table 1. In brief, 71% of the patients were
older than 50 years, 18% were de novo metastatic, 73% had
primary tumors larger than 2 cm, and 65% had axillary lymph
nodes involved at the time of diagnosis. The majority of the
tumors were HER2-negative (84%) and grade 2 (61%). Of interest,
the metastases from six patients lost ER expression in their
metastatic sample. The most represented primary ILC histological
subtypes were classic (56%); mixed non-classic (21%), and
trabecular (16%). The origin of the analyzed metastases is
consistent with the metastatic patterns observed for ILC
patients,28 with bone metastases being the most frequent (24%),
followed by metastases from reproductive organs and the skin
(both 14%), and metastases from the gastro-intestinal tract and
peritoneum (both 8%).
Incidence and distribution of ESR1 mutations in the retrospective
metastatic ILC cohort
We assessed the presence of ﬁve different ESR1 mutations: E380Q,
Y537S/C/N, and D538G. Five patients (6%) had a unique ESR1
mutation in the primary tumor (n= 3) or axillary lymph node
metastasis (n= 2), which was not detected in the matched distant
metastasis (Table 2). These mutations showed a variant allele
fraction ranging between 0.1 and 2.0% and were distributed as
follows: D538G (n= 3), Y537S (n= 1), and Y537N (n= 1). The
metastases from seven patients (9%) harbored ESR1 mutations,
which were absent from the interrogated primary samples (Table
3). Of these, patient #6 harbored the Y537S mutation in the skin
metastasis and the D538G mutation in the axillary lymph node
metastasis. Of interest, for two of these patients, two different
metastatic samples collected at a different time of disease
evolution displayed a different ESR1 mutational status. The ﬁrst
metastatic biopsy of patient #2 was taken at ﬁrst diagnosis of
recurrence and did not harbor an ESR1 mutation, while the
second, taken at progression two years later after she had
received an aromatase inhibitor, presented the D538G mutation.
Patient #78, who was diagnosed with de novo metastatic disease,
also had two metastases that were analyzed, the ﬁrst taken at
diagnosis which was negative and the second taken 1.3 years later
after being treated with letrozole, which harbored the E380Q
mutation.
Association of ESR1 mutations with clinical and pathological
features
We explored the associations between the presence of ESR1
mutations and clinico-pathological features. All but one patients
with ESR1 mutations were ≤ 55 years old at diagnosis and had
axillary lymph node metastasi(e)s. Also all but one patients were
treated with aromatase inhibitors, in the adjuvant and/or
metastatic setting before the metastatic biopsy was taken. This
means that the frequency of ESR1-mutated metastases is very
different according to endocrine therapy the patients received
before their metastatic biopsy: SERM (1/32, 3.1%), AI only (5/18,
27.8%), SERM+ AI (1/24, 4.2%), and no endocrine treatment (0/6,
0%). Three of the seven patients were de novo metastatic,
however for two of them their biopsy was taken several years after
diagnosis. Of interest, the metastasis from patient #67 harbored
three different ESR1 mutations, however this patient received only
adjuvant tamoxifen as endocrine treatment. We did not observe
any association with the speciﬁc histologic ILC variants and none
of the metastatic samples that lost ER expression presented an
ESR1 mutation.
Comparison of the prevalence and distribution of ESR1 mutations
between IDC and ILC patients
To compare the prevalence and distribution of ESR1 mutations
between IDC and ILC patients, we ﬁrst interrogated the metastases
from the MSKCC-IMPACT cohort (Fig. 1a–c). The distribution of the
ILC metastases is very similar to what we observed in our
retrospective series (Fig. 1b). We observed no statistically
signiﬁcant difference in the prevalence of ESR1 mutations, with
11.9% (71/595) of the IDC and 13.8% (16/116) of the ILC patients
harboring a mutation in at least one of the investigated
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metastases (p= 0.540, Fisher’s exact test). We then compared the
types of mutations and observed that the most frequent mutation
both in IDC and ILC is the D538G mutation, present in 38.5 and
56.3% of the IDC and ILC mutated samples, respectively. Some of
the less commonly reported mutations such as V422del, S463P,
L536H/P/R, and Y537N were only observed in metastases from IDC
patients. Of note, in the metastases from the ILC patients, the only
additionally detected mutation that we found and that was not
part of the ﬁve mutations we were interrogating in our series was
the L536Q mutation present in one metastasis. In this series, we
could not assess the presence of the mutations in the matched
primary samples, nor the ER status in the primary and metastatic
disease or the association with treatment, as these data were not
available. Given the key role of FOXA1 and GATA3 in the
transcription factor complex of ER,29 we aimed at investigating
the co-occurrence of mutations present in these genes with ESR1
mutations. Consistently with what has been observed in the
primary disease,3,5 we noticed a higher prevalence of GATA3
mutations in IDC (14.8%) compared to ILC (3.4%) metastases (p <
0.001, Fisher’s exact test). The only statistically signiﬁcant
association we observed was between ESR1 and GATA3 mutations
in IDC metastases, with 28.0% of the ESR1-mutated metastases
harboring also GATA3 mutations, compared to only 13.0% of the
ESR1 wild-type metastases (p= 0.002, Fisher’s exact test).
We further compared the prevalence and distribution of ESR1
mutations identiﬁed in ctDNA between IDC and ILC patients in the
SoFEA (NCT00253422) and PALOMA-3 (NCT01942135) trials (Fig.
1d). In these trials, the ESR1 mutational status was analyzed in 606
patients (445 from PALOMA-3 and 161 from SoFEA): 416 IDC, 76
ILC, and 117 with other histologies. There was no statistically
signiﬁcant difference in the overall incidence of ESR1 mutations
between the two main histologies with 29.6 and 26.3% reported in
samples from IDC and ILC patients, respectively (p= 0.680, Fisher’s
exact test). Consistently with the above results, we further did not
observe any difference in the distribution of the ESR1 mutations
between the two histologies.
Table 1. Patient and sample characteristics of the retrospective
metastatic ILC cohort
N (%)
Age at primary diagnosis
Median (min–max) 55 (33–81)
<50 23 (28.8)
≥50 57 (71.3)
De novo metastatic
No 66 (82.5)
Yes 14 (17.5)
Histological primary tumor size
<2 cm 20 (25.0)
≥2 cm 58 (72.5)
Unknown 2 (2.5)
Histological nodal status
Negative 27 (33.8)
Positive 52 (65.0)
Unknown 1 (1.3)
Histological grade primary
1 15 (18.8)
2 49 (61.3)
3 15 (18.8)
Unknown 1 (1.3)
PgR status primary
Negative 11 (13.8)
Positive 66 (82.5)
Unknown 3 (3.8)
HER2 status primary
Negative 67 (83.8)
Positive 6 (7.5)
Unknown 7 (8.8)
Ki67 primary
<20% 38 (47.5)
≥20% 25 (31.3)
Unknown 17 (21.3)
ER status metastasis
Negative 6 (7.5)
Positive 66 (82.5)
Unknown 8 (10.0)
Main histological subtype primary
Alveolar 1 (1.3)
Classic 45 (56.3)
Mixed non-classic (incl. pleomorphic) 17 (21.3)
Solid 3 (3.8)
Trabecular 13 (16.3)
Unknown 1 (1.3)
(Neo)Adjuvant chemotherapy
Yes 64 (80.0)
No 16 (20.0)
Organ metastatic samplea
Bone 20 (23.5)
GI tract 7 (8.2)
Local relapse 3 (3.5)
Liver 8 (9.4)
Lung 8 (9.4)
Table 1 continued
N (%)
Lymph nodes 6 (7.1)
Peritoneum 7 (8.2)
Reproductive organs 13 (15.3)
Skin 13 (15.3)
Timing metastatic sample
At ﬁrst diagnosis metastatic diseaseb 62 (77.5)
After ﬁrst diagnosis metastatic disease 18 (22.5)
Endocrine treatment before metastatic biopsy
SERM only 32 (40.0)
AI only 18 (22.5)
SERM and AI 24 (30.0)
No endocrine treatment 6 (7.5)
Duration endocrine treatment before metastatic biopsy
<2 years 21 (26.3)
2 to 4 years 14 (17.5)
>4 years 45 (56.3)
AI aromatase inhibitor, ET endocrine therapy, SERM selective estrogen
receptor modulator
aThe total number is >80 since several metastatic samples were analyzed
for some patients
bThis includes metastatic samples collected up to 3 months after ﬁrst
diagnosis of metastatic disease
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DISCUSSION
In this study, we aimed ﬁrst at evaluating ESR1 mutations in a
unique retrospective multi-centric cohort of metastatic ILC and
second at comparing their prevalence and distribution to
metastatic IDC using external cohorts. In our retrospective cohort,
ESR1-mutated metastases were detected in 9% of the patients. In
MSKCC-IMPACT,18 we observed a slightly higher rate of 13.8% and
11.9% in metastases from ILC and IDC patients. The lower rate
observed in our series might potentially be explained by the fact
that only 52% of the patients were treated with aromatase
inhibitors before their metastatic biopsy and by the fact that most
of the metastatic biopsies (78%) were taken early in the metastatic
phase. We could however not compare these two cohorts given
the lack of publicly available pathological and clinical data for
MSKCC-IMPACT. The even higher rates observed in SoFEA and
PALOMA-324 (29.6% and 26.3% in IDC and ILC patients,
respectively) are in line with the rates observed in ctDNA
studies15,21–25 and with the fact that the majority of the patients
received prior aromatase inhibitors. Globally, these comparisons
revealed no difference in prevalence of ESR1 mutations between
the two histologies. These results are also in line with two previous
studies.27,30 Bartels et al. reported ESR1mutations in 11/% (11/118)
and 11.4% (14/113) of IDC and ILC metastases, however this study
was limited to bone metastases.30 Toy et al. reported ESR1
mutations in 10.3% (72/698) and 14.2% (20/141) of IDC and ILC
samples, respectively, however these were a mixture of primary
tumors and metastases from recurring patients.27
With regard to the type of mutations present in ILC, we
observed that D538G is the most common mutation, present in
the metastatic disease from 57.1%, 56.3%, and 60.0% of the ILC
patients with ESR1-mutated metastases from our series, MSKCC-
IMPACT, and the SoFEA/PALOMA-3 ctDNA, respectively. Although
these values were numerically higher in ILC compared to IDC
patients, the difference was not statistically signiﬁcant. It has
recently been demonstrated that the different activating ESR1
mutations do promote a metastatic phenotype31 but are not
similar with regard to the efﬁcacy of ER antagonists.27 For
instance, Toy et al. observed that Y537S-mutated tumors, as
opposed to tumors harboring D538G, E380Q, or S463P mutations,
are associated with in vivo resistance to fulvestrant and should
therefore be treated with a more potent ER antagonist.27 The
fraction of Y537S mutations among all ESR1 mutations was
variable across the series: 42% in our series, 18.8% in MSKCC-
IMPACT, and 15% in SoFEA/PALOMA-3. This suggests that the type
of ESR1 mutation should be carefully evaluated for optimal
endocrine treatment decision.
This study is to the best of our knowledge the largest study of
ER-positive BC comparing the presence of ESR1 mutations in
matched primary and metastatic samples. Our data do not
support the hypothesis that rare ESR1-mutated clones are selected
for in the primary tumor during disease progression since we did
not detect the mutations identiﬁed in the primary disease in the
matched metastases. Nevertheless, we cannot rule out that these
mutations could be present in another metastatic lesion. Also, we
did not detect the mutations present in the metastases in the
matched primary samples, although here we cannot exclude that
we missed the minor subclone present in the primary tumor
despite having interrogated several geographical regions when-
ever possible with a very sensitive technology.
The main limitations of our study are linked to the retrospective
nature of our cohort, with the inherent heterogeneity in treatment
and timing of metastatic sampling. Also, the choice of ddPCR was
implying that only pre-deﬁned mutations could be investigated.
The full spectrum of ESR1 mutations was however interrogated in
the MSKCC-IMPACT cohort.18 Only the L536Q mutation was
detected in one ILC metastasis from this cohort in addition to the
ﬁve mutations we were focusing on in our retrospective cohort,
suggesting that we did not miss too many mutations in our
cohort. In our series, ddPCR was chosen for its high-sensitivity to
increase the chance of detecting rare mutations. Indeed a study
Table 2. Characteristics of patients and samples from the retrospective metastatic ILC cohort with mutated primary mammary or positive axillary
lymph node samples
Pt6 Pt38 Pt48 Pt54 Pt103
ESR1 mutations (AF) D538G (1%)-both PLN
samples
D538G (2%)-in only 1 of
the 4 P samples
Y537N (0.1%) in PLN D538G (2%) in P E380Q (5.5%) in P
Nr of P samples evaluated 2 4 1 1 1
Nr of PLN samples evaluated 2 0 1 1 0
Nr of M samples evaluated 1 2 1 22 1
Age at P diagnosis 49 65 45 33 55
PgR (P) + − + + +
HER2 (P) − − − − +
Grade (P) 3 1 2 2 2
Ki67 (P) 10 5 37 15 NA
Histotype (P) Mixed NC Classic Trabecular Classic Mixed NC
pT 1 2 2 1 4
pN 1 2 3 3 0
De novo metastatic Yes No No No No
Type ET AI SERM+ AI SERM AI AI
Duration ET (yrs) 7.2 8 5 2.8 1.4
Setting ET Met Adj Adj Adj Met
Time between diagnosis and
sampling
7.8 0 0 0 0
Organ samples Bone Peritoneum Bone Liver Peritoneum
AF allelic frequency, AI aromatase inhibitor, ET endocrine therapy, NA not available, Mixed NC mixed non-classic, P primary, PLN positive lymph node, SERM
selective estrogen receptor modulator
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comparing NGS and ddPCR showed that they could detect three
times more ESR1 mutations with ddPCR than NGS.32 Finally, the
last limitation of this study was that it focused on ESR1 mutations
only, and was therefore not reporting on other potential
mechanisms of endocrine resistance involving directly (ESR1
gain/ampliﬁcation/translocation/fusion) or indirectly ESR1 (such
as partners from the transcription factor complex29). We never-
theless explored the co-occurrence of mutations present in two
key partners, GATA3 and FOXA1, known to be frequently altered in
ER-positive BCs. We only observed a positive association between
ESR1 and GATA3 mutations in metastases from IDC patients, the
biological implications of which should be further investigated
through functional studies.
To conclude, we have shown here using the largest series of
matched primary/metastasis ILC cohort and an ultra-sensitive
technology, that there was no patient presenting an identical ESR1
mutation in the early setting and in metastatic disease.
Furthermore, the study did not identify differences in terms of
prevalence and type of ESR1 mutations between the two most
common BC histological subtypes.
PATIENTS AND METHODS
Patients and samples from the multi-centric retrospective ILC
cohort
We considered the patients from six European Institutions (Institut Jules
Bordet-Brussels, Cliniques Universitaires Saint-Luc-Brussels, GZA Zieken-
huizen-Antwerp, Institut Paoli-Calmettes-Marseille, Institut Curie-Paris,
Istituto Europeo di Oncologia-Milan) that were fulﬁlling the following
criteria: (1) no distinct invasive neoplastic components other than ILC at
central revision; (2) ER-positive status of the primary tumor; (3) minimal
tumor cellularity of 20% (if < 20%, then only considered if macrodissection
could be done); (4) availability of >100 ng of DNA from a formalin-ﬁxed
parafﬁn-embedded (FFPE) block of the primary tumor, metastasis, and
non-invaded tissue. Whenever possible, multiple FFPE blocks were
considered for the primary tumor, the axillary, and distant metastases.
DNA extraction from FFPE samples was performed using the QIAamp DNA
FFPE Tissue Kit and concentration was measured using the Qubit
ﬂuorometer (Life technologies). The project has been approved by the
ethics committee of the Institut Jules Bordet (N°2504). Given the
retrospective nature of the study, the ethics committee did not require
the patients to sign an informed consent.
ddPCR
The presence of the mutations E380Q, Y537S/C/N, and D538G was
assessed using custom designed mutation-speciﬁc assays in a total
reaction volume of 23 µl consisting in 1x ddPCR supermix for probes
without dUTP, 0.9 µM each primer, 0.25 µM probe, and 10–100 ng of DNA.
All ddPCR experiments were performed using the in house Bio-Rad QX200
System. ddPCR assay speciﬁcity was assessed using negative and positive
controls, consisting of normal DNA from breast reduction and synthetic
oligonucleotides harboring the mutations of interest, respectively.
QuantaSoft v.1.7.4 software (Bio-Rad) was used for data analysis. Sample
positivity was determined following Bio-Rad guidelines. Absolute copies of
mutant DNA and wild-type DNA were estimated from the Poisson
distribution.
ESR1 mutations in external cohorts
We downloaded the targeted sequencing and clinical data from MSKCC-
IMPACT18 from cbioportal.org19,20 in April 2018. We considered only the
metastases from female BC patients with the Oncotree code “BRCANOS”,
“BRCNOS” and “IDC” code as IDC patients and with the “ILC” code as ILC
patients. With regard to the ESR1 mutations, we only considered those
reported to be “Gain-of-function” or “Likely Gain-of-function” according to
OncoKB.33 For the GATA3 and FOXA1 mutations, we considered the
mutations annotated as “hotspot” or “3D hotspot” or “Likely Oncogenic” or
“Predicted Oncogenic” in cbioportal.org. We further queried the results
obtained in ctDNA from the SoFEA (NCT00253422) and PALOMA-3
(NCT01942135) trials.24 In these studies, the presence of the ESR1
mutations was assessed by ddPCR.
Table 3. Characteristics of patients and samples from the retrospective metastatic ILC cohort with mutated metastatic samples
Pt1 Pt2 Pt6 Pt58 Pt62 Pt67 Pt78
ESR1 mutations (AF) Y537S
(0.24%)
D538G
(22.3%)
Y537S (27%) D538G
(16.9%)
D538G
(15.0%)
Y537S (8.0%)
Y537N (6.4%)
D538G (0.8%)
E380Q (5.5%)
Nr of primary samples (P & PLN)
evaluated
7 3 5 2 2 2 1
Age 45 42 49 52 61 54 55
PgR + − + + − + +
HER2 − − − − − − +
Grade 2 2 3 2 2 NA 2
Ki67 20 10 10 20 18 15 NA
Histotype Trabe-
cular Mixed NC Mixed NC Trabecular Classic Classic Mixed NC
pT 1 1 1 2 2 1 4
pN 1 1 1 2 3 3 0
De novo metastatic Yes No Yes No No No Yes
Type AI SERM+ AI AI AI AI SERM AI
Duration (yrs) 3.8 2.8+ 1.9 7.2 8 6.8 4.7 1.4
Setting Met Adj+
met Met Adj Adj Adj Met
Time between diagnosis and sampling 3.9 2.0 7.8 0 0 0 1.3
Organ samples Bone Bone Bone Liver Bone Peritoneum Peritoneum
Patients 6 and 78 had metastases that were sampled at different times during disease evolution and only the second one harboring the ESR1 mutation was
reported in this table
AF allelic frequency, AI aromatase inhibitor, ET endocrine therapy, NA not available, Mixed NC mixed non-classic, P primary, PLN positive lymph node, SERM
selective estrogen receptor modulator
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Statistical analyses
The associations between the ESR1 mutational status and clinico-
pathological variables were assessed using the Fisher’s exact test. All
statistical tests were two-sided at the 0.05 signiﬁcance level and conducted
under R 3.4.1 (http://www.r-project.org/).
Reporting summary
Further information on experimental design is available in the Nature
Research Reporting Summary linked to this article.
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Fig. 1 Comparison of prevalence and distribution of ESR1 mutations in the IDC and ILC metastatic disease. a Frequency of the different ESR1
mutations in IDC and ILC in the metastases from the MSKCC-IMPACT cohort. b Distribution of the different types of metastases sequenced
from IDC and ILC patients, and proportion of the ESR1-mutated (mut) and wild-type (WT) metastases in the MSKCC-IMPACT cohort. c Co-
occurrence of ESR1 mutations with GATA3 and FOXA1 mutations in IDC and ILC patients in the MSKCC-IMPACT cohort. d Frequency of the
different ESR1 mutations in IDC and ILC in ctDNA from the SoFEA and PALOMA-3 trials
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